NCT00679497

A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection

A Phase I Study of MVA-B in Healthy Volunteers at Low Risk of HIV Infection

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Juan A. Arnaiz · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical trial is to study a modified pox viral vector considering: 1. HIV subtype B accounts for the most frequent virus strain in Europe and North America, as well as in many parts of the world. 2. This novel vaccinia construct expressing HIV subtype B gag, pol, env and nef antigens is to be studied in humans for the first time.

Conditions

• HIV Infections

Interventions

Type	Name	Description
BIOLOGICAL	MVA-B	* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) -\~ 1 x 10e8 pfu/ml * 3 immunisations at week 0, 4 and 16
BIOLOGICAL	Placebo	-3 immunisations at week 0, 4 and 16

Timeline

• Start date: 2008-06-01
• Primary completion: 2010-03-01
• Completion: 2010-12-01
• First posted: 2008-05-19
• Last updated: 2013-02-22

Locations

2 sites across 1 country: Spain